ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) ...
BCG Attorney Search has released a new report offering an extensive analysis of the leading law firms across major legal markets in the United States. The repor ...
ImmunityBio Inc. IBRX shares are up during Thursday’s premarket session as the company has completed enrollment in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results